The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
-
BUSINESS Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
-
BUSINESS DSP to Establish Sales Force for Anticancer Drugs in North America
August 3, 2012
-
BUSINESS Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban
August 2, 2012
-
REGULATORY Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
-
BUSINESS Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
-
REGULATORY MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
-
BUSINESS DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
-
BUSINESS Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
-
BUSINESS Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
-
ORGANIZATION EFPIA Submits Opinion Letter to MHLW Calling for Review of Priority Focus on Japanese Companies for Blood Plasma Products
July 27, 2012
-
BUSINESS Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
-
REGULATORY MHLW Asks Sanofi Pasteur to Consider Reducing Price of IPV
July 25, 2012
-
ORGANIZATION Hiroshima Wholesale FTC Sees “Gradual Effects” in Correcting Labor Services in Cooperation with Pharmacists
July 25, 2012
-
BUSINESS Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
-
BUSINESS HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
-
BUSINESS Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
-
REGULATORY Cost-Effective Assessments to Be Limited to Technologies for Which Alternatives Are Available: CSIMC
July 19, 2012
-
BUSINESS China to Overtake Japan as Second-Biggest Drug Market by 2016: IMS Health
July 18, 2012
-
ORGANIZATION 4.5 Bil. Yen Tax Hike Estimated in FY2012 Tax Reform: JPMA
July 17, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…